Mobility decreased; Arthritis; Shoulder pain; Interchange of vaccine products; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (Mobility decreased), ARTHRITIS (Arthritis), ARTHRALGIA (Shoulder pain) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for an unknown indication.    Concomitant products included TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced MOBILITY DECREASED (Mobility decreased), ARTHRITIS (Arthritis), ARTHRALGIA (Shoulder pain) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, MOBILITY DECREASED (Mobility decreased) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown and ARTHRITIS (Arthritis) and ARTHRALGIA (Shoulder pain) had not resolved.            No treatment details were provided.  Company comment: This is a spontaneous case concerning a adult male patient of unknown age with no reported medical history and with co-suspect product of Adalimumab (Humira) for unspecified indication and vaccine history of receiving 3 doses of Covid-19 BioNTech, who experienced the unexpected non-serious event of arthritis and unexpected non-serious event of mobility decreased and the expected non-serious event of arthralgia. The events occurrence was unknown with respect to the booster dose of mRNA-1273 vaccine administration. No other information surrounding the events was reported. The outcome of the events arthritis and arthralgia was reported as not resolved while the event mobility decreased the outcome was reported as unknown. The co-suspect product of Adalimumab (Humira) remain confounder for the events arthritis, arthralgia, and mobility decreased. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This is a spontaneous case concerning a adult male patient of unknown age with no reported medical history and with co-suspect product of Adalimumab (Humira) for unspecified indication and vaccine history of receiving 3 doses of Covid-19 BioNTech, who experienced the unexpected non-serious event of arthritis and unexpected non-serious event of mobility decreased and the expected non-serious event of arthralgia. The events occurrence was unknown with respect to the booster dose of mRNA-1273 vaccine administration. No other information surrounding the events was reported. The outcome of the events arthritis and arthralgia was reported as not resolved while the event mobility decreased the outcome was reported as unknown. The co-suspect product of Adalimumab (Humira) remain confounder for the events arthritis, arthralgia, and mobility decreased. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.